SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
809I second your view. Few note from NBIX UBS presentation. Insomnia: -They are eMiljenko Zuanic-10/11/2001
808You know, Harry, biotech investors everywhere owe you one big "thanks"scaram(o)uche-10/10/2001
807Neurocrine Biosciences [NASDAQ: NBIX $32.02] 12-Month Price Target: $57.00 F20Icebrg-10/1/2001
806Monday October 1, 5:50 am Eastern Time Press Release SOURCE: Neurocrine Biosciensmh-10/1/2001
805MOPGCW- I was referring to NBIX. Miljenko- I think the GSK discussions Biotech Jim-9/26/2001
804BJ< <<My bet is that the binding domains of the BP and the receptor arMiljenko Zuanic-9/26/2001
803"I hope the stock does well, though, since I still hold half my shares frommopgcw-9/26/2001
802I feel that it is important not to overestimate the value of peptide SAR studiesBiotech Jim-9/25/2001
801From the most recent filing: "We believe that the remaining net proceeds fmopgcw-9/25/2001
800Why you think that it may not? <<The majority of positions eliminated areMiljenko Zuanic-9/25/2001
799but if medichem does not survive??mopgcw-9/25/2001
798Very important part of the overall picture. Reason that NBIX sign CRF X-ray collMiljenko Zuanic-9/25/2001
797Monday September 24, 3:02 pm Eastern Time Press Release SOURCE: National Brain TMiljenko Zuanic-9/24/2001
796sort of a tacky release, but I'm certain that their application will be apprscaram(o)uche-9/10/2001
795Scott or other TA gurus, Let see can we (on paper or in real who like) play thiMiljenko Zuanic-8/28/2001
794The good news is that NBIX is in good position with good news - clinical, financScott H. Davis-8/28/2001
793FWIW:from the Briefing.com Short Stories(free) section: Neurocrine Biosci (NBIX)Jim Oravetz-8/28/2001
792NBIX-GSK agreement may as well be written as (plain English): *^@?[***][***]@!%Miljenko Zuanic-8/19/2001
791Fireing on all cylinders! :) Hope they do not *overheat*. MiljenkoMiljenko Zuanic-7/31/2001
790<i>-- An orally active GnRH antagonist development candidate has been. sescaram(o)uche-7/31/2001
789Tuesday July 31, 7:30 am Eastern Time Press Release SOURCE: Neurocrine Biosciescaram(o)uche-7/31/2001
788Thanks, Miljenko. <i>BTW, Sonata does not have any next day residual effeBiomaven-7/27/2001
787Peter, Half-life time is only one component of the broad PK/PD picture. Also, hMiljenko Zuanic-7/27/2001
786"TAK’s melanacortin analogue" Sounded to me like he said "TakedaBiomaven-7/27/2001
785Did anyone get to hear the CC? I could not get the web site to respond and gaveIRWIN JAMES FRANKEL-7/24/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News